Evidence map›Paper›PMID 36034440›Full record

SynthesisFrontiers in endocrinology2022

Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis.

Jinjing Wei, Ruxin Wang, Haowen Ye, Ying Wang, Lihong Wang, Xiaofang Zhang

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Comparing GLP-1 agonists versus other weight loss interventions on risk of atrial fibrillation recurrence after catheter ablation: a meta-analysis.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Semaglutide as adjunctive therapy to catheter ablation in obesity-related paroxysmal atrial fibrillation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Association of Glucagon-Like Peptide-1 Receptor Agonist with Incident Atrial Fibrillation.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. GLP-1RA Use and Thyroid Cancer Risk.JAMA otolaryngology-- head & neck surgery · 2025
    Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jinjing WeiDepartment of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, China.
Ruxin WangDepartment of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, China.
Haowen YeDepartment of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, China.
Ying WangDepartment of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, China.
Lihong WangDepartment of Endocrinology and Metabolism, First Affiliated Hospital of Jinan University, Guangzhou, China.
Xiaofang ZhangDepartment Clinical Experimental Center, First Affiliated Hospital of Jinan University, Guangzhou, China.
First Affiliated Hospital of Jinan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: An update of a systematic review and meta-analysis of the risk of arrhythmias and their subtypes in type 2 diabetic patients receiving glucagon-like peptide 1 receptor agonist (GLP-1RA) medication according to data from the Cardiovascular Outcome Trial(CVOT). Methods: Randomized controlled trials (RCT) on GLP-1RA therapy and cardiovascular outcomes in type 2 diabetes mellitus patients published in full-text journal databases such as MEDLINE (via PubMed), Embase, Clinical Trials.gov, and the Cochrane Library from establishment to March 1, 2022 were searched. We assessed the quality of individual studies by the Cochrane risk-of-bias algorithm. RevMan 5.4.1 software was use for calculating meta-analysis. Results: A total of 60,081 randomized participants were included in the data of these 8 GLP-1RA cardiovascular outcomes trials. Pooled analysis reported no significant effect on total arrhythmia [RR=0.96, 95% CI (0.96, 1.05), Conclusion: In type 2 diabetic patients, treatment with GLP-1RA has no significant effect on the risk of major arrhythmias but significantly reduces the risk of hypoglycemia and pneumonia.

Indexed as

Atrioventricular BlockDiabetes Mellitus, Type 2HypoglycemiaGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsInfant, NewbornRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsArrhythmiaGlucagon-like peptide 1 receptor agonistMeta-analysisSystematic ReviewsT2DM

Identifiers

PMID36034440
PMCPMC9403613
OpenAlexW4291015985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.